Brief: Spectrum Pharmaceuticals Presents Positive Data For Poziotinib In First-Line NSCLC Patients
07/03/2022 11:07
March 7 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O :
* SPECTRUM PHARMACEUTICALS PRESENTS POSITIVE DATA FOR
POZIOTINIB
IN FIRST-LINE NSCLC PATIENTS WITH HER2 EXON 20 INSERTION
MUTATIONS
* SPECTRUM PHARMACEUTICALS INC - DATA PRESENTED AT ESMO TAT
FROM
COHORT 4 OF ZENITH20 CLINICAL TRIAL MET PRIMARY ENDPOINT
Source text for Eikon: ID:nBwtNNsba
Further company coverage: SPPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary